Literature DB >> 20189638

HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.

Bradley M Mathers1, Louisa Degenhardt, Hammad Ali, Lucas Wiessing, Matthew Hickman, Richard P Mattick, Bronwyn Myers, Atul Ambekar, Steffanie A Strathdee.   

Abstract

BACKGROUND: Previous reviews have examined the existence of HIV prevention, treatment, and care services for injecting drug users (IDUs) worldwide, but they did not quantify the scale of coverage. We undertook a systematic review to estimate national, regional, and global coverage of HIV services in IDUs.
METHODS: We did a systematic search of peer-reviewed (Medline, BioMed Central), internet, and grey-literature databases for data published in 2004 or later. A multistage process of data requests and verification was undertaken, involving UN agencies and national experts. National data were obtained for the extent of provision of the following core interventions for IDUs: needle and syringe programmes (NSPs), opioid substitution therapy (OST) and other drug treatment, HIV testing and counselling, antiretroviral therapy (ART), and condom programmes. We calculated national, regional, and global coverage of NSPs, OST, and ART on the basis of available estimates of IDU population sizes.
FINDINGS: By 2009, NSPs had been implemented in 82 countries and OST in 70 countries; both interventions were available in 66 countries. Regional and national coverage varied substantially. Australasia (202 needle-syringes per IDU per year) had by far the greatest rate of needle-syringe distribution; Latin America and the Caribbean (0.3 needle-syringes per IDU per year), Middle East and north Africa (0.5 needle-syringes per IDU per year), and sub-Saharan Africa (0.1 needle-syringes per IDU per year) had the lowest rates. OST coverage varied from less than or equal to one recipient per 100 IDUs in central Asia, Latin America, and sub-Saharan Africa, to very high levels in western Europe (61 recipients per 100 IDUs). The number of IDUs receiving ART varied from less than one per 100 HIV-positive IDUs (Chile, Kenya, Pakistan, Russia, and Uzbekistan) to more than 100 per 100 HIV-positive IDUs in six European countries. Worldwide, an estimated two needle-syringes (range 1-4) were distributed per IDU per month, there were eight recipients (6-12) of OST per 100 IDUs, and four IDUs (range 2-18) received ART per 100 HIV-positive IDUs.
INTERPRETATION: Worldwide coverage of HIV prevention, treatment, and care services in IDU populations is very low. There is an urgent need to improve coverage of these services in this at-risk population. FUNDING: UN Office on Drugs and Crime; Australian National Drug and Alcohol Research Centre, University of New South Wales; and Australian National Health and Medical Research Council. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189638     DOI: 10.1016/S0140-6736(10)60232-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  313 in total

1.  No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs.

Authors:  Brandon D L Marshall; M-J Milloy; Thomas Kerr; Ruth Zhang; Julio S G Montaner; Evan Wood
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

2.  Estonia at the threshold of the fourth decade of the AIDS era in Europe.

Authors:  Kaja-Triin Laisaar; Radko Avi; Jack DeHovitz; Anneli Uusküla
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-11       Impact factor: 2.205

3.  Prospective effects of traumatic event re-exposure and post-traumatic stress disorder in syringe exchange participants.

Authors:  Jessica M Peirce; Robert K Brooner; Ken Kolodner; Rebecca L Schacht; Michael S Kidorf
Journal:  Addiction       Date:  2012-10-05       Impact factor: 6.526

4.  Data Collection and Harmonization in HIV Research: The Seek, Test, Treat, and Retain Initiative at the National Institute on Drug Abuse.

Authors:  Redonna K Chandler; Shoshana Y Kahana; Bennett Fletcher; Dionne Jones; Matthew S Finger; Will M Aklin; Kathleen Hamill; Candace Webb
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

Review 5.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Authors:  Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

6.  Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: evidence from cross-sectional surveys.

Authors:  Sigrid Vorobjov; Don C Des Jarlais; Katri Abel-Ollo; Ave Talu; Kristi Rüütel; Anneli Uusküla
Journal:  Int J Drug Policy       Date:  2012-10-01

7.  Impact of incarceration experiences on reported HIV status and associated risk behaviours and disease comorbidities.

Authors:  Robert Heimer; Olga S Levina; Victoria Osipenko; Monica S Ruiz; Boris Sergeyev; Aleksander V Sirotkin; Inna Vyshemirskaya
Journal:  Eur J Public Health       Date:  2015-09-16       Impact factor: 3.367

8.  Evaluating network-level predictors of behavior change among injection networks enrolled in the HPTN 037 randomized controlled trial.

Authors:  Laramie R Smith; Steffanie A Strathdee; David Metzger; Carl Latkin
Journal:  Drug Alcohol Depend       Date:  2017-04-05       Impact factor: 4.492

9.  Factors associated with illicit opioid use in methadone maintenance treatment clients in 5 Provinces, China.

Authors:  Weixiu Li; Ziyun Wang; Zhimin Liu
Journal:  Environ Health Prev Med       Date:  2016-10-03       Impact factor: 3.674

10.  The causal effect of opioid substitution treatment on HAART medication refill adherence.

Authors:  Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.